@ARTICLE{
author={Goel Shom,Tan Antoinette R,Rugo Hope S,Aftimos Philippe,Andric Zoran G,Beelen Andrew Paul,Zhang Jingshan,Yi John S,Malik Rajesh K,O'Shaughnessy Joyce},
year={2022},
title={Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2},
journal={FUTURE ONCOLOGY},
volume={18},
number={33},
pages={3701-3711},
document_type={Article},
} 

@ARTICLE{
author={Goel Shom,O'Shaughnessy Joyce,Tan Antoinette R,Milev-Krastev Boris,Rugo Hope S,Aftimos Philippe Georges,Yardley Denise A,Andric Zoran G,Wolfgang Curt Douglas,Sorrentino Jessica,Tao Wenli,Beelen Andrew Paul,Malik Rajesh K,Jain Sarika},
year={2021},
title={Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={39},
number={15},
pages={-},
document_type={Meeting Abstract},
}